Purpose: There is an urgent need for the development of novel positron emission tomography (PET) tracers for glioma imaging. In this study, we developed a novel PET probe ([ 18 
Introduction
Malignant gliomas are the most common primary brain tumors and are characterized by invasive growth and recalcitrance to therapy. The use of pathology for the diagnosis, grading, and classification of gliomas is confounded by tumor heterogeneity and sampling errors associated with obtaining tissue specimens through biopsy or surgical resection. Hence, imaging is frequently used to support clinical decisions by providing a non-invasive method to characterize the whole tumor and metastases [1] . Though ubiquitously employed clinically, X-ray computed tomography (CT) and magnetic resonance imaging (MRI) provide little molecular information attributable to the pathology of disease and tend to poorly discriminate margins, particularly where tumors are highly infiltrative. As another non-invasive imaging modality, positron emission tomography (PET) imaging overcomes many of the limitations associated with conventional brain tumor imaging modalities and offers unique advantages including improved sensitivity and the ability to differentiate tissues based upon molecular characteristics. Currently, 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG) is the most widely used PET tracer for brain tumor imaging in the clinic [2] . However, due to tracer accumulation in normal brain tissues, PET imaging using [ 18 F]FDG can only generate modest to poor tumor-to-background ratios. Thus, there remains a strong unmet clinical need to develop and validate novel molecular imaging ligands for the detection and characterization of gliomas.
Translocator protein (TSPO) is an 18 kDa membrane protein typically localized to the outer mitochondrial membrane. Formerly known as the peripheral benzodiazepine receptor (PBR), TSPO participates in a variety of cellular functions, including steroid biosynthesis, cholesterol metabolism, cell proliferation, and apoptosis. [3] . Accordingly, TSPO expression is elevated in numerous clinically important diseased states, including neuroinflammation [4] [5] [6] [7] [8] and cancer [9] [10] [11] [12] . As a hallmark of aggressive tumors, TSPO expression has been linked with disease progression and diminished survival in oncology.
A variety of TSPO ligands have been reported for imaging a number of cancers, including colon cancer [13] , breast cancer [14] [15] [16] , and glioma [17] [18] [19] [20] [21] . Since TSPO tends to have elevated expression in brain tumor tissues while maintaining low expression in normal brain, it is ideal to use TSPO PET tracers to visualize and quantify glioma [22] . In our previous studies, N- [17] have been used for glioma imaging. Further, we reported the synthesis and structure activity relationship (SAR) analysis of a library of novel pyrazolopyrimidines [23] , which led to the discovery of a novel ligand 2-(5,7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo [1,5-a] pyrimidin-3-yl)-N,N-diethylacetamide (VUIIS1008) that exhibited a 36-fold enhancement in binding affinity compared to the previously reported TSPO ligand, DPA-714 [17, 23] . Herein, we further modified the five and seven positions of the pyrazolopyrimidinal scaffold and discovered a novel TSPO ligand VUIIS1018A (Fig. 1) , which features a 700-fold and a 20-fold enhancement in binding affinity when compared with DPA-714 and VUIIS1008, respectively [17, 23] .
To evaluate its in vivo performance in C6-glioma imaging, we prepared the radiolabeled ligand [ 
Materials and Methods

Chemicals
[ 3 H]PK 11195 was purchased from PerkinElmer. Phosphatebuffered saline (PBS) and CytoScint ES Liquid Scintillation Cocktail were purchased from MP biomedicals. 2,4-Octanedione was purchased from Alfa Aesar. All other synthesis reagents were purchased from Sigma-Aldrich Chemical Company and used as supplied.
Ligand and Radioligand Precursor Preparation
As shown in Scheme 1 (see Electronic Supplementary Material: ESM), 2A and 2B can be prepared via a two-step synthetic route starting from previously reported compound 1 [23, 24] . Compound 1 is combined with octane-2,4-dione to afford the desired pyrimidine ring heterocycle, followed by de-protection of the methyl ether to reveal the phenol moiety via reaction with hydrogen bromide, HBr. Further reaction of 2A and 2B with the appropriate tosylates produced 3A (VUIIS1018A), as the cold analog of the F-18 labeled probe, 3B (VUIIS1018B) and 4A, as a precursor for the radiosynthesis of the PET tracer [ 18 F]VUIIS1018A.
Structure characterization was performed using liquid chromatography-mass spectrometry (LCMS), H-1 and C-13 NMR (see ESM).
In Vitro TSPO-Binding Assay PO 4 buffer (pH 6.7) and ethanol (47.5/52.5, v/v) at 6.0 ml/min. The product was collected directly into 140 ml of water (deionized), passed through a C-18 Sep-Pak Plus (Waters, Milford, MA, USA), and eluted with 200 proof ethanol (1.0 ml) then saline (9.0 ml) into a sterile vial. Radiochemical purities were greater than 90 % in all cases and the typical specific activities were 4203 Ci/mmol (156 TBq/mmol) or greater.
Animals
All studies involving animals were conducted in compliance with federal and institutional guidelines. For glioma studies, healthy male Wistar rats were stereotactically inculcated in the right hemisphere with 1.0 × 10 5 C6 glioma cells (American Type Culture Collection, Manassas, VA, USA) 2 weeks prior to imaging. Rats were affixed with venous and arterial catheters prior to the MRI and PET/CT study. 
MRI
PET was co-registered with MRI for anatomical comparison. In this study, rats were secured prone in a radiofrequency coil (38-mm inner diameter) and placed in a 4.7T MRI imaging system (Varian Inc., Palo Alto, CA, USA). Body temperature was maintained at 37°C using heated airflow. In order to properly position the rats for subsequent scans, a multi-slice gradient-echo sequence (repetition time, 150 ms; echo time, 3.5 ms; matrix, 128 × 128; field of view, 40 × 40 mm 2 ; slice thickness, 2 mm) was employed to acquire seven slices in each imaging plane (axial, coronal, and sagittal direction). Following this, MRI imaging was performed using a T 2 -weighted fast spin-echo scan with 8 echoes and 8-ms echo spacing (effective echo time, 32 ms). The 8 coronal slices of 2 mm thickness (16 acquisitions) were collected using a repetition time of 2000 ms; field of view 32 × 32 mm 2 and a matrix of 128 × 128.
PET and CT Acquisition
In rats with confirmed tumors, PET and CT were performed within 24 h of MRI. Rats were administered [
18 F]VUIIS1018A via jugular catheter while in a microPET Focus 220 scanner (Siemens, Knoxville, TN, USA). Data were collected in listmode format for 60 or 90 min, followed by CT (microCAT II; Siemens) for attenuation correction. The dynamic PET acquisition was divided into 32 frames (12 frames (10 s per frame) for the first 2 min, 3 frames (1 min per frame) for the following 3 min, and 17 frames (5 min per frame) for the remainder of the scan). Within each frame, the raw data were binned into 3D sinograms with a span of three and ring difference of 47. The scatter and attenuation corrections were applied. The tomographic images (128 × 128 × 95) with voxel sizes of 0.095 × 0.095 × 0.08 cm 3 were obtained by reconstructing the sinograms using a two-dimensional ordered-subsets expectationmaximization algorithm with 16 subsets and 4 iterations. Attenuation correction was accomplished by generating an attenuation map from the CT images. The CT images were first co-registered with PET, then segmented and projected into sinogram space with a span of 47 and ring difference of 23. Three-dimensional volumes of interest were drawn over tumor and contralateral brain using ASIPro (Siemens) in order to generate time-activity curves (TACs).
In vivo Uptake, Blocking, and Displacement of [ In vivo uptake (n = 7), blocking (n = 3), and displacement studies (n = 3) were carried out in glioma-bearing rats. Rats were administered 1.1 ± 0.3 mCi (40.9 ± 10. 18 F]VUIIS1018A in rats. Following centrifugation, plasma was extracted with a mixture of acetonitrile/water (340 μl, 7/1 v/v). The mixture was again centrifuged and the supernatant spotted on silica/glass TLC plates (Waterman, GE healthcare, USA). TLC plates were scanned using an AR-2000 radio-TLC imaging scanner (Bioscan, France) according to published methods [25] .
Image Analysis and Modeling
For PET imaging analysis, TACs were generated by manually drawing three-dimensional volumes of interest over contralateral brain and tumor using ASIPro (Siemens). The arterial input function (AIF) was generated from plasma sampling (15 μl) during the dynamic imaging and corrected for metabolism of the parent ligand. For the following analysis, a two-tissue, four-rateconstant kinetic model was explored using PMOD (PMOD technologies LLC, Zurich) (Fig. 4) . In this model, C p represents the concentration of [ 18 F]VUIIS1018A in the plasma. C t represents non-specific and free tracer in the tissue. C m represents the specific binding of the tracer to TSPO in the outermitochondria membrane. The four parameters of K 1 , k 2 , k 3 , and k 4 reflect the transport or binding rates of the tracer. In this specific study, K 1 indicates the perfusion rate of the probe from plasma to tissue (ml/min/g), while k 2 reflects the clearance rate for the tracer from tissue to plasma (1/min). k 3 and k 4 represent the specific binding rates and dissociation rates of the tracer (1/min), respectively.
Calculation of the total distribution volume (V T ) was performed based on the estimated kinetic parameters of K 1 , k 2 , k 3 , and k 4 for different tissues. Normally, V T is regarded as the sum of specific (V S ) and non-specific distribution (V ND ) (Eqs. 1, 2, and 3).
The binding potential (BP ND ) can be characterized as:
For receptor binding:
where B max is the concentration of the receptor in the tissue, while K d is the equilibrium dissociation constant, which represents the concentration of radioligand occupying half of the maximum receptor population. Calculation of the BP ND parameter map was done using the Simplified Reference Tissue Model 2 (SRTM2) method [26] in the PMOD software package for the normal 60-min dynamic PET scan with [ 
Results
SARs and Binding Affinity
The TSPO affinities of a series of pyrazolopyrimidine probes, including DPA-714, VUIIS1008, VUIIS1018A, and VUIIS1018B were analyzed by performing competitive binding assays against the isoquinoline carboxamide [ 3 H]PK 11195, a well-known TSPO ligand, in C6 glioma cell lysates (Fig. 1) . Strikingly, the new probe VUIIS1018A exhibits an exceptional TSPO binding affinity (IC 50 = 16.2 pM), which is almost 700-fold higher than DPA-714 (IC 50 = 10.9 nM) and 20-fold higher than VUIIS1008 (IC 50 = 0.3 nM). More interestingly, VUIIS1018B, the regioisomer of VUIIS1018A, featured an IC 50 value of 0.1 μM, which is 6000-fold lower than VUIIS1018A. The significant difference in binding affinity indicated that modification of the 5-position of the pyrazolopyrimidine ring with a bulky n-butyl group can decrease the binding affinity dramatically, while the same modification on the 7-position leads to elevated binding affinity as compared to the parent compounds DPA-714 and VUIIS1008. 18 F]VUIIS1018A was evaluated in C6 glioma-bearing rats. Uptake (n = 7) of [
18 F]VUIIS1018A was evaluated using 60-min dynamic PET scans (Fig. 2) . Similar to what was observed in earlier studies [23] , the C6 glioma can be detected with [ 18 F]VUIIS1018A PET imaging (Fig. 2b, c) and the anatomic location of the PET signal corresponded to the tumor location as seen with T 2 -weighted MRI (Fig. 2a) . [ 18 F]VUIIS1018A exhibited robust accumulation in C6 gliomas with negligible accumulation observed in normal brain (Fig. 2c, d ). This result is consistent with the elevated levels of TSPO in this model compared with surrounding, non-tumor brain as demonstrated through TSPO immunohistochemistry (IHC) [17-19, 23, 25, 27] and autoradiography [28, 29] in previous studies. As shown in the time-activity curves (TACs), rapid delivery of the tracer to both tumor and normal brain can be observed right after the tracer injection (Fig. 2e) . [ 18 F]VUIIS1018A cleared very rapidly and did not accumulate to an appreciable extent in normal brain. In contrast, [ 18 F]VUIIS1018A rapidly accumulated in tumor tissue and increased modestly over time. Ultimately, a tumor-to-background ratio of 3:1 was achieved at the end of the 60-min scan (Fig. 2e) .
Binding Specificity and Reversibility in Tumor
To further evaluate the specificity of tracer accumulation, a blocking study (n = 3) was conducted by administering cold [ (Fig. 3a, b) . A blocking dose of 10 mg/kg [ 19 F]VUIIS1018A led to significantly elevated circulating plasma radioactivity compared with the unblocked scenario (Fig. 3c) . Furthermore, uptake of [ 18 F]VUIIS1018A in tumor tissue was significantly reduced in the blocking study. An overall reduction in tumor PET signal of 48.3 ± 2.8 % (mean ± SD, n = 3) was achieved with the injection of cold compound (Fig. 3c) (Fig. 3e) . Accordingly, analysis of the time-activity curves (TACs) from this displacement study indicated that after the injection of [ 19 F]VUIIS1018A, the radioactivity of the tumor was reduced approximately 62.0 ± 8.0 % (mean ± SD, n = 3), compared with the tumor uptake in the PET analysis without displacement (Fig. 3f) .
Compartmental Modeling
Pharmacokinetic modeling was used to more closely examine the uptake and clearance characteristics of [
18 F]VUIIS1018A in tumor and normal brain. As with other TSPO PET ligands that we have evaluated in this setting [17, 18] , the pharmacokinetics of [ 18 F]VUIIS1018A more closely fit a 2-tissue, 4-rate constant kinetic model in both tumor and normal brain (Fig. 4) . K 1 and k 2 , terms reflecting delivery and efflux from a nonbinding compartment, respectively, were similar for [ (Fig. 5) . As shown in Fig. 5b, d [23, 25] . In these studies, the TSPO probes displayed significant capability for discriminating the tumors from the surrounding normal brain. More importantly, using compartmental analysis, the TSPO levels could be quantitatively assayed in tumors [17, 18, 25] . However, potential drawbacks associated with these prior radiotracers included (1) tracer accumulation in the normal brain which reached a sufficient level to prevent the 18 F]VUIIS1018A in the plasma. C t represents non-specific and free tracer in the tissue. C m represents the specific binding of the tracer to TSPO in the outer-mitochondria membrane. The four parameters of K 1 , k 2 , k 3 , and k 4 reflect the transport or binding rates of the tracer. In this specific study, K 1 indicates the perfusion rate of the probe from plasma to tissue, while k 2 reflects the clearance rate for the tracer from tissue to plasma. k 3 F]VUIIS1018A exhibited an improved tumor-tobackground ratio, a higher specific-to-non-specific binding ratio and a higher tumor binding potential, which made the new tracer a better candidate for detecting tumors with modest TSPO expression profiles.
Conclusion
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